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Abstract 21 
 22 
Current chemotherapy against African sleeping sickness, a disease caused by the 23 
protozoan parasite Trypanosoma brucei, is limited by toxicity, inefficacy, and drug 24 
resistance. Nucleoside analogues have been successfully used to cure T. brucei-infected 25 
mice, but they all have the limitation of being taken up by the P2 nucleoside transporter, 26 
which, when mutated, is a common cause of multidrug resistance in T. brucei. We report 27 
here that adenine arabinoside (Ara-A) and the newly tested drug 9-(2´-Deoxy-2´-fluoro-28 
ß-D-arabinofuranosyl) adenine (FANA-A) are instead taken up by the P1 nucleoside 29 
transporter, which is not associated with drug resistance. Similar to Ara-A, FANA-A was 30 
also found to be resistant to cleavage by methylthioadenosine phosphorylase, an enzyme 31 
that protects T. brucei against the antitrypanosomal effects of deoxyadenosine. Another 32 
important factor behind the selectivity of nucleoside analogues is how well they are 33 
phosphorylated within the cell. We found that the T. brucei adenosine kinase had a higher 34 
catalytic efficiency with FANA-A than the mammalian enzyme, and T. brucei cells 35 
treated with FANA-A accumulated high levels of FANA-A triphosphate, which even 36 
surpassed the level of ATP and led to cell cycle arrest, inhibition of DNA synthesis, and 37 
accumulation of DNA breaks. FANA-A inhibited nucleic acid biosynthesis and parasite 38 
proliferation with EC50 values in the low nanomolar range, whereas mammalian cell 39 
proliferation was inhibited in the micromolar range. Both Ara-A and FANA-A, in 40 
combination with deoxycoformycin, cured T. brucei-infected mice, but FANA-A did so 41 
at a 100 times lower dose than Ara-A. 42 
 43 
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Introduction  44 
 45 
Trypanosoma brucei causes African sleeping sickness in humans and Nagana in cattle 46 
and is transmitted between its mammalian hosts by tsetse flies (1, 2). The disease is 47 
characterized by two stages. Initially the parasites are restricted to circulating in the blood 48 
and lymph systems, but in the advanced stages of the disease they are also found in the 49 
cerebrospinal fluid, which leads to coma and death if the patient is not treated. There is 50 
no existing vaccine, and available treatments are specific to the disease stage and the 51 
parasite subspecies. High toxicity, complex administration protocols, and drug resistance 52 
all contribute to the urgent need for new therapies.  53 
 54 
T. brucei lacks the pathway for de novo purine biosynthesis and is absolutely dependent 55 
on exogenous purines that are taken up from the body fluids of its hosts (3). As a 56 
consequence, the trypanosomes have evolved an array of efficient nucleoside and 57 
nucleobase transporters for purine uptake (4). The efficient transporters and downstream 58 
purine salvage enzymes can be exploited by developing antitrypanosomal substrate 59 
analogues that utilize the powerful salvage systems in T. brucei and subsequently kill the 60 
parasite by interfering with nucleotide-dependent reactions and/or nucleic acid 61 
biosynthesis. 62 
  63 
It is not only ribonucleosides that are salvaged by T. brucei. The parasite is also able to 64 
salvage some deoxyribonucleosides, which are taken up by high-affinity nucleoside 65 
transporters (5, 6) and subsequently phosphorylated by thymidine kinase and adenosine 66 
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kinase (7-10). Thymidine kinase phosphorylates thymidine and deoxyuridine (7), 67 
whereas adenosine kinase is able to salvage adenosine and deoxyadenosine (9). It has 68 
been shown that higher levels of dATP accumulate in T. brucei than in mammalian cells 69 
when treated with high concentrations of deoxyadenosine in the growth medium and that 70 
this accumulation is followed by T. brucei growth inhibition and lysis (11, 12). This 71 
effect is less prominent at lower concentrations of deoxyadenosine because T. brucei 72 
methylthioadenine phosphorylase (TbMTAP) cleaves this substrate into adenine and 73 
deoxyribose-1-phosphate, and thereby rescues the parasite from the cytotoxicity of 74 
deoxyadenosine (11). At higher concentrations of deoxyadenosine, this protective system 75 
is inhibited by its reaction product, adenine, which allows the deoxynucleoside to be 76 
phosphorylated by adenosine kinase instead, leading to subsequent buildup of toxic levels 77 
of dATP in the cell (11). TbMTAP is relevant for drug development because adenosine 78 
kinase substrate analogues need to be resistant to TbMTAP cleavage in order to be 79 
effective against the parasites.  80 
 81 
Nucleoside/deoxynucleoside analogs are commonly used as drugs for cancer therapy and 82 
antiviral treatments (13). One advantage of using nucleoside analogs against second-stage 83 
sleeping sickness is that many of them can cross the blood brain barrier via transporters 84 
used for the uptake of nucleosides needed by the brain (14). T. brucei bloodstream forms 85 
express two different purine nucleoside transporters, P1 and P2 (5, 15). The T. brucei P2 86 
transporter has received much attention because of its role in multidrug resistance. It is 87 
involved in the uptake of diamidines and the melaminophenyl arsenicals, which are two 88 
of the main groups of antitrypanosomal agents known to be effective against T. brucei (5, 89 
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15). The P2 transporter is particularly important for the uptake of diaminazene aceturate 90 
(Berenil), a diamidine drug used against Nagana in cattle (16). Experience using this drug 91 
in cattle has shown that the trypanosomes rapidly become resistant (16), and specific 92 
resistance mutations in the P2 transporter have been experimentally verified (17). 93 
Moreover, the P2 transporter was shown to be the sole transporter for the furamidine 94 
trypanocides (18) that until recently were in clinical trials against sleeping sickness (19), 95 
and it has also been implicated as one of the main T. brucei transporters for melarsoprol 96 
and pentamidine (15, 20). A main reason for the easily acquired resistance is that the 97 
transporter is encoded by a single gene, TbAT1 (5, 21). Mutations of this gene can 98 
mediate drug resistance with no major loss in purine nucleoside transport, which can still 99 
occur by the P1 transporter activity as well as by the various nucleobase transporters (22). 100 
In contrast, P1 nucleoside transporters are encoded by at least half a dozen genes spread 101 
throughout the genome, and the different genetic variants of the P1 transporter seem to 102 
have similar substrate specificities (23, 24). It is therefore unlikely that mutations or the 103 
deletion of only one of them could cause resistance to a nucleoside analogue.  104 
 105 
Most of the antitrypanosomal adenosine/deoxyadenosine analogs developed so far, 106 
including cordycepin, 2-fluorocordycepin, and tubercidin, are mainly taken up by the P2 107 
nucleoside transporter (25, 26), which constitutes a problem with respect to cross-108 
resistance to existing therapies. Our aim in this study was to identify novel 109 
antitrypanosomal adenosine analogues that are taken up by the P1 transporter and, due to 110 
the many genetic variants, less likely to become ineffective as a result of gene mutation. 111 
Other criteria that need to be fulfilled for an efficient antitrypanosomal nucleoside 112 
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analogue exploiting the adenosine kinase-mediated salvage pathway are that it should be 113 
resistant to cleavage by TbMTAP and it should be a good substrate of T. brucei adenosine 114 
kinase.  115 
 116 
Material and methods 117 
 118 
TbMTAP cleavage assay. TbMTAP assays were performed as described previously with 119 
recombinantly expressed and purified enzyme (11). Briefly, the enzyme was diluted in a 120 
buffer containing 50 mM potassium acetate, 50 mM Tris-HCl pH 7.4, and 0.05% Tween-121 
20 prior to use in the enzyme assay. Enzyme activity was checked by incubating the 122 
enzyme with the compound in question in the presence of 50 mM KH2PO4 (adjusted to 123 
pH 7.4 with KOH) for 30 min at 37°C. The reaction was stopped by incubation at 100°C 124 
for 2 min, and the reaction products were analyzed by HPLC as described (11) to 125 
determine if the compound had been cleaved by TbMTAP. The amount of enzyme was 126 
adjusted for each substrate to give an assay that was linear over the 30-min incubation 127 
period.  128 
 129 
T. brucei and mammalian cell culture. T. brucei bloodstream forms were cultured at 130 
37°C in 5% CO2 and humidified atmosphere in HMI-9 medium supplemented with 10% 131 
(v/v) heat-inactivated fetal bovine serum (Thermo Fischer Scientific (Gibco), Waltham, 132 
MA, USA) (27). Several clonal T. brucei brucei cell lines were used, all derivatives of 133 
the Lister 427 strain (http://tryps.rockefeller.edu/trypsru2_pedigrees.html). This includes 134 
the Lister 427 strain in de Koning´s laboratory, TC221 in Hofer´s laboratory (a previous 135 
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gift from Prof. Opperdoes, Universite Catholique Louvain, Brussels, Belgium), and the 136 
B48 multidrug-resistant cell line in which the TbAT1/P2 gene first had been deleted by 137 
homologous recombination (TbAT1-KO) (28) and the knockout cells had subsequently 138 
been subject to continuous exposure to increasing levels of pentamidine in vitro (29). Re-139 
introduction of the TbAT1 gene in this line created B48 + P2 (17), resulting in a higher 140 
and more stable expression of the P2 transporter, which appears to be downregulated in 141 
vitro when it is expressed only from its original locus (18). Mouse BALB/3T3 fibroblasts 142 
(ATCC no. CCL-163) were cultivated as monolayers at 37°C in 5% CO2 and a 143 
humidified atmosphere in Dulbecco’s modified Eagle’s medium (Sigma) supplemented 144 
with 10% (v/v) heat-inactivated fetal bovine serum, glutamine (0.584 g/l), and 10 ml/l of 145 
100× penicillin, and streptomycin (Thermo Fischer Scientific (Gibco)). Human 146 
promyelocytic leukemia cells (HL-60 cells, ATTC number CCL-240) were grown as 147 
suspensions of cells under similar conditions as the Balb/3T3 cells with the only 148 
difference being that RPMI (Thermo Fischer Scientific (Gibco)) was used instead of 149 
Dulbecco´s modified Eagle´s medium.    150 
 151 
Drug sensitivity assays. FANA-A and other test compounds were serially diluted in 152 
HMI-9 medium, and 100 µl was added to each well in two rows on a 96-well plate. 153 
Cultures of bloodstream-form T. brucei were diluted to 2 × 105 cells/ml in HMI-9, and 154 
100 µl of cells was added to all wells. The plate was incubated at 37°C and 5% CO2 for 155 
48 h, after which 20 µl of 0.5 mM of resazurin sodium salt (Sigma) in phosphate-buffered 156 
saline (PBS) was added to each well and the plate was incubated for a further 24 h. 157 
Fluorescence was measured with 540 nm excitation and 590 nm emission using an 158 
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Infinite M200 microplate reader (Tecan Group, Männedorf, Switzerland). EC50 values 159 
were calculated after plotting the fluorescence against the test compound concentration 160 
using a sigmoid curve with a variable slope (Prism 5.0, GraphPad software, LA Jolla, 161 
CA, USA).  162 
 163 
Nucleotide pool measurement. NTP and dNTP pools from T. brucei TC221 cells were 164 
extracted as described previously (12). Briefly, T. brucei cells (108 cells) were lysed with 165 
a trichloroacetic acid-MgCl2 solution and centrifuged, and the supernatant was 166 
subsequently extracted twice with freon-triocylamin to remove the trichloroacetic acid. 167 
The resulting nucleotide extract (20 µl) was loaded onto a 100 mm × 4.6 mm ACE 3 AQ 168 
column (Advanced Chromatography Technologies, Aberdeen, Scotland) run at 1 ml/min. 169 
The mobile phase consisted of 11.3% (v/v) methanol, 80 mM KH2PO4, and 2 mM 170 
tetrabutylammonium bisulfate, and the final solution was adjusted to pH 6 with KOH. 171 
NTPs as well as FANA-A diphosphates and triphosphates were quantified by comparing 172 
the peak heights to the results with a standard nucleotide solution. This HPLC protocol 173 
was optimized for the determination of the FANA-A nucleotides and cellular NTPs, 174 
whereas the cellular dNTPs were too low to be separated reliably from minor background 175 
peaks.  176 
 177 
Measurement of [5,6- 3H]-uracil incorporation into T. brucei nucleic acids. 178 
Growing T. brucei TC221 (1.8–2 × 108 cells) were collected by centrifugation at 1,800 × 179 
g for 2 min and resuspended in 10 ml fresh medium. The resuspended cells were 180 
incubated with 2 µM deoxycoformycin (dCF) for 30 min before treatment with various 181 
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concentrations of FANA-A for 1 h in the presence of 10 µCi [5,6-3H]-uracil (Moravek 182 
Biochemicals Inc., Brea, CA). Extraction and precipitation of 3H-labeled nucleic acids 183 
from T. brucei were performed as described, and the amount of radioactivity in the RNA 184 
and DNA was measured (9). 185 
 186 
Assessing cell cycle progression in T. brucei. The cell cycle progression of 187 
bloodstream-form T. brucei (strain Lister 427) treated with FANA-A was assessed by 188 
visualizing the DNA in the nuclei and kinetoplasts using the fluorescent dye DAPI (4,6- 189 
diamidino-2-phenylindole) followed by microscopic analysis as previously described 190 
(30). Briefly, 50 µl of a trypanosome suspension (5 × 105 cells/ml) was spread onto a 191 
glass microscope slide and left to dry before methanol fixation overnight at 20oC. The 192 
slides were then rehydrated with 1 ml PBS for 10 min and then allowed to dry (but not 193 
totally). One drop of Vectashield antifade mounting medium with DAPI (Vector 194 
Laboratories Inc., USA) was added to the slides and spread out before covering with the 195 
coverslip. The slides were then viewed under UV light using a Zeiss Axioplan 196 
microscope with a Hamamatso digital camera and Openlab software. For each sample, 197 
500 cells were counted and scored for their DNA configuration as 1N1K, 1N2K, 2N2K 198 
(Early), or 2N2K (Late) (where: N = nucleus; K = kinetoplast; ‘Early’ = no ingression 199 
furrow; and ‘Late’ = cell division has started with an obvious ingression furrow). 200 
Samples were taken at 0, 4, 8, 12, 16, and 24 hours, and untreated cultures were used as 201 
controls. 202 
 203 
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Assessment of DNA integrity. DNA fragmentation after exposure of T. brucei 204 
bloodstream forms (Lister 427) to FANA-A (with or without dCF) was determined as 205 
previously described (31). Drug-free and phleomycin (Sigma)-treated cells were used as 206 
negative and positive controls, respectively. Briefly, the cell density was adjusted to 1 × 207 
106 cells/ml and the cells were incubated with or without the test compounds for 12 h. 208 
The cells were fixed in 5 ml of 1% (w/v) paraformaldehyde in PBS, then centrifuged at 209 
400 × g for 5 min and washed twice in 5 ml PBS. Finally, 5 ml of 70% ethanol was added 210 
to the sample, which was kept at −20oC for at least 1 hour. The sample was then 211 
centrifuged for 5 min at 400 × g. The pellets were resuspended in 1 ml of transporter 212 
assay buffer (see below) and centrifuged for 5 min at 400 × g. The resuspension-213 
centrifugation step was performed twice to remove any residual ethanol. The presence of 214 
DNA strand breaks in the FANA-A-treated trypanosomes was observed by flow 215 
cytometry using the APO-BrdU TUNEL assay kit supplied by Life Technologies (catalog 216 
no. A23210) according to the manufacturer’s protocol where double-stranded breaks are 217 
extended by terminal deoxynucleotide transferase in the presence of dNTPs and 218 
bromodeoxyuridine (BrdU) triphosphate followed by immunolabeling of BrdU in DNA.  219 
 220 
Adenosine kinase assay. Recombinant T. brucei adenosine kinase was expressed and 221 
purified as described previously but using a concentration of 100 mM imidazole to elute 222 
the protein in the Nickel-NTA agarose chromatography step (9). The enzyme assay 223 
contained 3 mM ATP, 6.4 mM MgCl2, 100 mM KCl, and 50 mM Tris-HCl pH 7.6. 224 
Various concentrations of potassium phosphate (from a 100 mM KH2PO4-K2HPO4 pH 225 
7.6 stock solution) and substrate (usually FANA-A) were included as described in the 226 
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figure legends. The enzyme (0.05 μg/reaction) was diluted prior to use in the assay with a 227 
buffer consisting of 50 mM Tris-HCl pH 7.6, 50 mM KCl, 0.1 mM dithiothreitol, and 228 
0.05% (v/v) Tween-20. The 50 μl assay mixture was incubated at 37oC for 10 min and 229 
stopped by heating the sample for 2 min at 100oC. The separation of the reaction product 230 
from substrate, ATP, and other UV-absorbing compounds was performed by HPLC using 231 
a 50 mm × 2.1 mm Ultracore 2.5 SuperHexylPhenyl column (Advanced Chromatography 232 
Technologies) and a mobile phase containing 65 mM KH2PO4, 2 mM 233 
tetrabutylammonium bisulfate and 7% (v/v) methanol adjusted to pH 6 with KOH. The 234 
flow-rate was 0.4 ml/min and the injection volume 5 μl.  235 
 The short form of human adenosine kinase (32) was expressed, purified, and 236 
assayed in a similar way as described for the T. brucei enzyme except that the induction 237 
was performed for 10 hours at 30oC (instead of 3 hours at 37oC). The his-tag removal 238 
step was skipped in the purification protocol because it is known that the tag does not 239 
influence enzyme activity (32). The enzyme assay conditions were the same as for the T. 240 
brucei enzyme, and no adjustment to the amount of enzyme in micrograms was necessary 241 
because the molecular masses of the T. brucei and human (tagged) adenosine kinases are 242 
very similar in size (38 and 39 kDa, respectively). The bacteria expressing the human 243 
adenosine kinase (32) were part of a collection of mammalian adenosine kinases, bacteria 244 
and antibodies obtained as a kind gift from James Bibb at the University of Texas 245 
Southwestern Medical Center. All adenosine kinase assays were verified to be in the 246 
linear range with respect to time and protein amount.  247 
 248 
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Uptake assays. The assays were performed exactly as described previously (33, 34). 249 
Bloodstream forms of T. brucei cultures were harvested, washed with assay buffer (33 250 
mM HEPES, 98 mM NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM 251 
NaH2PO4, 0.3 mM MgCl2, 23 mM NaHCO3, and 14 mM glucose, pH 7.3) and 252 
resuspended at 108 cells/ml. The cells were incubated for 30 s with 0.1 µM [2,8-3H]-253 
adenosine in the presence or absence of competitive substrates. The uptake assay for the 254 
P1 transporter was performed with the T. brucei B48 knockout strain that lacks the P2 255 
transporter. The uptake assay for the P2 transporter was performed with the same strain 256 
transfected with an expression construct carrying the P2 gene (B48 + P2), and in this case 257 
the experiment was performed in the presence of 1 mM inosine to saturate the P1 258 
transporter. After the 30 s incubation with [3H]-adenosine and competitors, the incubation 259 
was stopped with ice-cold unlabeled substrate (1 mM in assay buffer) and centrifuged 260 
through oil (13,000 × g for 1 min). This incubation time is well within the linear range of 261 
uptake as shown for both bloodstream and procyclic T. brucei (35). The cell pellet was 262 
transferred to a scintillation tube, and radioactivity was counted by a scintillation counter. 263 
 264 
Adenosine deaminase assays. The presence of adenosine deaminase in the culture 265 
medium was measured by incubating the medium with up to 1 mM adenosine or FANA-266 
A for up to 48 h at 37oC. The sample was centrifuged through a 3 kDa cutoff filter 267 
(Nanosep 3K Omega, PALL Corp., Port Washington, NY) and diluted 40 times in water. 268 
Subsequently, 5 µl of the diluted sample was analyzed by HPLC. The chromatography 269 
was performed on a 50 mm × 2.1 mm ACE Ultracore 2.5 SuperC18 column (Advanced 270 
Chromatography Technologies, Aberdeen, UK) using an aqueous mobile phase 271 
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containing 7% methanol and 42 mM ammonium acetate adjusted to pH 6 with acetic 272 
acid. The flow rate was 0.4 ml/min.  273 
 274 
Mouse experiments. T. brucei TC221 bloodstream forms (20,000 cells) were injected 275 
intraperitoneally into black C57BL/6 mice. After confirmation of parasites in the blood 276 
(generally 3 days after injection), treatment started with an intraperitoneal injection of 277 
PBS buffer supplemented with 2 mg/kg FANA-A in combination with 0.25 mg/kg dCF. 278 
Similar experiments were also performed with 200 mg/kg Ara-AMP in combination with 279 
dCF. The doses were given twice daily on every alternate day for a total of 5 days (i.e. in 280 
the morning and afternoon on day 1, 3, and 5). Control mice were treated with dCF 281 
mixed in PBS or with only PBS. Blood samples were regularly collected from the tail and 282 
checked for the presence of T. brucei cells, and the mice were considered to be cured if 283 
they were parasite-free for 60 days after the last dose. 284 
 285 
Results 286 
 287 
Selection of adenosine analogues. One of the requirements for an adenosine kinase 288 
substrate analogue to be efficient against T. brucei is that it must be resistant to cleavage 289 
within the cell. Previous experiments have shown that adenine arabinoside (Ara-A) is a 290 
very poor substrate for the TbMTAP enzyme that cleaves deoxyadenosine and that Ara-A 291 
sensitivity against TbMTAP-knockdown trypanosomes was unaltered, indicating that its 292 
intracellular cleavage by TbMTAP is insignificant (11). In addition to being cleavage 293 
resistant, Ara-A has good antitrypanosomal activity in the sub-micromolar range (9, 11). 294 
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Thus we tested the cleavage resistance and antitrypanosomal activity of other 295 
deoxyadenosine and adenosine analogues having different 2´-substituents pointing in the 296 
same direction as the 2´-OH group in Ara-A (Fig. 1). Two such compounds are 297 
commercially available – FANA-A, which is a deoxyadenosine analogue with a fluorine 298 
atom at this position, and 2´-C-methyladenosine, which is an adenosine analogue with a 299 
methyl group at this position (Fig. 1). In addition, we also tested two variants of FANA-A 300 
containing a halogen at the 2-position of the base to make them resistant to the adenosine 301 
deaminase activity present in mammalian serum. These drugs included 2-fluoro-FANA-A 302 
(2F-FANA-A), which was a kind gift from Jack Secrist at the Southern Research 303 
Institute, and clofarabine, an anticancer agent used clinically (36). The advantage of the 304 
deamination-resistant drugs is that they can be used as single agents in chemotherapy, 305 
whereas other adenosine analogues generally need to be combined with adenosine 306 
deaminase inhibitors such as dCF in order to be stable in circulation.  307 
 308 
Resistance to cleavage by TbMTAP. The selected compounds were tested in enzyme 309 
assays with TbMTAP. As shown in Table 1, all of the new compounds were even more 310 
resistant to cleavage than Ara-A. In all four cases, the enzyme activity was below or very 311 
close to the detection limit of the experiment. For comparison, the activity with the native 312 
substrates methylthioadenosine, deoxyadenosine, and adenosine were more than 1000 313 
times higher than any of the nucleoside analogues evaluated. We also tested the cleavage 314 
of the different drugs in T. brucei cell extracts to determine if the drugs were recognized 315 
by other nucleoside cleavage activities in T. brucei. The main purine nucleoside cleavage 316 
activity in T. brucei cells is inosine-adenosine-guanosine nucleoside hydrolase (IAG-317 
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NH), an enzyme that efficiently cleaves purine ribonucleosides but has very low activity 318 
on deoxyribonucleosides (37). The cleavage activity in the cell extract was below the 319 
detection limit for all of the nucleoside analogues tested, whereas the activity with 320 
adenosine, which was used as the positive control in the experiment, was ~1000 times 321 
higher than the detection limit (Table 1).  322 
 323 
FANA-A is an efficient inhibitor of T. brucei proliferation. FANA-A was by far the 324 
TbMTAP-resistant adenosine analogue with the greatest effect on T. brucei proliferation, 325 
with an EC50 value of 2.8 nM (Fig. 2A, Table 2). The EC50 value of 2´-C-326 
methyladenosine was 300 nM, which is in a similar range as reported for Ara-A (9, 11). 327 
Both FANA-A and 2´-C-methyladenosine were also very selective, as indicated by the 328 
much higher EC50 values against the mammalian reference cell lines  (Table 2), with 329 
FANA-A achieving selectivity indexes of 1900 and 790 (compared to Balb/3T3 and HL-330 
60 cells, respectively). However, the addition of fluoro or chloro substituents at the 2-331 
position of the nucleobase resulted in a reduced effectiveness against T. brucei 332 
proliferation. This effect can be attributed to these compounds being poor substrates of 333 
adenosine kinase, as predicted by previous molecular modeling studies with this enzyme 334 
(26). Clearly, the 2-position substitutions are poorly tolerated by adenosine kinase, and 335 
this is directly correlated to the size of the substituent because the chloro-substituted 336 
analogue clofarabine (2-chloro-FANA-A) displayed very low trypanocidal activity and 337 
the mammalian cells were much more sensitive than the trypanosomes.  338 
 339 
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FANA-A is phosphorylated in T. brucei cells and inhibits DNA synthesis. In 340 
mammalian cells, it is well-established that fludarabine, clofarabine, cladribine, and other 341 
nucleoside analogues lacking a 2´-OH group oriented as in ribonucleotides are 342 
phosphorylated in the cell and subsequently inhibit DNA synthesis indirectly via 343 
inhibition of ribonucleotide reductase and directly via inhibition of DNA polymerase 344 
(38). Inhibition of ribonucleotide reductase is in most cases due to the fact that the 345 
analogue mimics dATP as an overall negative regulator of activity, a type of regulation 346 
that T. brucei lacks (12). Nucleotide pool analysis of FANA-A-treated T. brucei cells 347 
showed that the parasites accumulated high levels of intracellular FANA-A 5´-348 
diphosphates and triphosphates, which increased above the level of ATP and became the 349 
dominant nucleotides in the cell (Fig. 2B). The concomitant reduction in the ATP pool, 350 
which was previously observed with deoxyadenosine-treated and Ara-A-treated 351 
trypanosomes (11, 12), was only modest in the case of FANA-A, indicating that this is 352 
probably not a significant factor contributing to the growth inhibition, which occurs at 353 
much lower FANA-A concentrations than needed to reduce the ATP levels. A radioactive 354 
tracer experiment showed that FANA-A blocked nucleic acid biosynthesis in the 355 
parasites (Fig. 2C–D). When parasites were grown in the presence of 3H-uracil and 356 
various concentrations of FANA-A, the incorporation of radiolabel in DNA was strongly 357 
inhibited, even at a FANA-A concentration of 0.1 µM (Fig. 2C). At higher concentrations 358 
of the drug, RNA synthesis was also inhibited (Fig. 2D). In principle, the results in Fig. 359 
2C-D could also be indirect effects caused by altered metabolism of the uracil that we 360 
used as a probe or by FANA-ATP competing with ATP-dependent reactions in the cell. 361 
However, the low concentrations of FANA-A and the short time (1 h) needed to give an 362 
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effect on DNA synthesis is a strong indication of specificity. For comparison, much 363 
higher concentrations were needed to obtain a large accumulation of FANA-ATP in the 364 
parasite (Fig. 2B). In addition, FANA-A does not resemble uracil in structure and the 365 
levels of UTP were normal in cells treated with the analogue (Fig. 2B). Unfortunately, 366 
the effect on the dNTP pools could not be determined accurately in these experiments 367 
because the FANA-A nucleotides interfered with the HPLC analysis. More experiments 368 
were therefore needed to confirm that the inhibition of DNA synthesis was a direct effect 369 
and not a cause of altered dNTP pools (see below).    370 
 371 
We performed a series of experiments to assess whether FANA-A directly inhibits DNA 372 
synthesis (Fig. 3). Visual inspection of cultured T. brucei by fluorescence microscopy of 373 
DAPI-stained cells showed that the cell cycle distribution of trypanosomes treated with 374 
0.2 µM FANA-A was similar to control cells during the initial hours after treatment. 375 
However, the treated cells gradually started to accumulate in the G1 stage with one 376 
nucleus and one kinetoplast (increasing from 60% of the cells in the G1 stage at the 377 
beginning of treatment to >90% after 24 h) (Fig. 3A). Concomitantly, the percentage of 378 
cells in all other cell cycle stages decreased. At the FANA-A concentration used, DNA 379 
synthesis was nearly completely inhibited (Fig. 2C) explaining why the change in cell 380 
cycle distribution takes 15 h even though a normal cell cycle is only 6 h. The 381 
accumulation of cells in the G1 stage means that they cannot pass the restriction point to 382 
reenter S-phase. For comparison, there was no change in cell cycle distribution in T. 383 
brucei treated with only dCF (Fig. S1). In order to determine if the altered cell cycle in 384 
FANA-A-treated T. brucei is due to DNA damage, we performed a TUNEL assay for the 385 
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detection of double-strand breaks. The FANA-A-treated parasites accumulated DNA 386 
breaks, and this effect was even higher if the FANA-A was protected from deamination 387 
by co-administration of dCF (Fig. 3B and Supplementary Fig. S2). The extent of DNA 388 
breaks was almost as high as with phleomycin, which was used as a positive control in 389 
the experiment. The induction of DNA breaks indicates that FANA-A interferes directly 390 
with the accuracy of DNA replication. 391 
 392 
Adenosine kinase activity. The first phosphorylation step is often rate limiting for the 393 
formation of nucleoside analogue diphosphates and triphosphates in the cell (39). In order 394 
to determine the reason for the selectivity of FANA-A against T. brucei, the recombinant 395 
adenosine kinase activity with FANA-A as the substrate was compared to that of the 396 
human adenosine kinase (Fig. 4). Mammalian and T. brucei adenosine kinases are known 397 
to be dependent on phosphate ions for optimal enzyme activity when adenosine is the 398 
substrate (9, 40). With FANA-A, the phosphate stimulation was fairly modest and was 399 
saturated already at 5 mM phosphate with both enzymes (Fig. 4A). An experiment with 400 
adenosine was also included for the human enzyme in order to highlight the difference in 401 
activity compared to FANA-A. With adenosine, the effect of phosphate ions was much 402 
stronger, and the activity continued to increase over the whole range of phosphate 403 
concentrations tested (Fig. 4A). The main conclusion from a drug development 404 
perspective is that FANA-A is a better substrate for the T. brucei adenosine kinase than 405 
for the human enzyme and that this conclusion is valid regardless of the phosphate 406 
concentration. The two enzymes were also studied using a fixed phosphate concentration 407 
of 5 mM and varying substrate concentrations to obtain Michaelis–Menten parameters 408 
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(Fig. 4B). The T. brucei adenosine kinase activity had both a higher kcat than the human 409 
enzyme (3.5 ± 0.3 s−1 vs. 0.99 ± 0.04 s−1, calculated per polypeptide) and a slightly more 410 
favorable KM (55 ± 16 µM vs. 96 ± 11 µM). 2F-FANA-A was also tested on the T. brucei 411 
enzyme, and it was found to be a much less favorable substrate (kcat: 0.151 ± 0.006 s−1, 412 
KM: 84 ± 10 μM), explaining why the sensitivity of the trypanosome cells to this 413 
compound was two orders of magnitude lower than to FANA-A (Table 2).  414 
 415 
FANA-A is taken up via the P1 nucleoside transporter family in T. brucei. 416 
Exhaustive characterization of purine transport activities in T. brucei has shown that the 417 
P1 and P2 transporters are the only transporters that facilitate the uptake of adenosine or 418 
its analogs in bloodstream forms of the parasite  (4, 5, 25, 33). By comparing the FANA-419 
A sensitivity of T. brucei cells (Lister 427-parent strain) with that of multidrug-resistant 420 
cells (strain B48) that lack both the P2 transporter and the high-affinity pentamidine 421 
transporter (HAPT) (29) and the same cells carrying a plasmid for stable expression of 422 
the P2 gene (strain B48 + P2) (17), it was possible to determine if the P2 nucleoside 423 
transporter plays a significant role in FANA-A uptake. As shown in Table 3, the 424 
sensitivity to pentamidine, which is known to be taken up by both the P2 nucleoside 425 
transporter and HAPT (later identified to be the aquaporin TbAQP2 (41)), was 426 
dramatically reduced in the B48 strain and was partially restored when the P2 transporter 427 
was reintroduced. A complete reversion was not expected because the cells still lacked 428 
HAPT. In contrast, the sensitivity to FANA-A or 2F-FANA-A was not decreased in the 429 
multidrug-resistant cells, indicating that the P2 transporter is not important for the uptake 430 
of the drugs. Instead, a slight but significant increase in the sensitivity could be observed 431 
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in the P2 knockout compared to the parent strain, possibly because of compensatory 432 
upregulation of the P1 transporter in the absence of the P2 transporter. The reintroduction 433 
of the P2 transporter on a high-expression plasmid (B48 + P2 cells) caused only a ~30% 434 
increase in the FANA-A (+dCF) sensitivity compared to the B48 strain. This indicates 435 
that either FANA-A is a very poor substrate for the P2 transporter or uptake through the 436 
P1 transporter is already so efficient that it does not limit the antitrypanosomal effects of 437 
FANA-A. 438 
 439 
Interestingly, Table 3 also shows that there was an order of magnitude difference in 440 
FANA-A sensitivity between experiments in the absence or presence of dCF. This 441 
indicates that the heat-inactivation procedure used to inactivate enzymes in the serum for 442 
the preparation of growth medium does not seem to be sufficient to disable all of the 443 
adenosine deaminase activity. This conclusion was verified in experiments where the 444 
deamination of deoxyadenosine in cell-free growth medium was checked by HPLC. 445 
Deoxyadenosine was nearly completely converted to deoxyinosine if incubated at 37°C 446 
for 48 h in growth medium containing heat-inactivated serum (Fig. 5A). In the presence 447 
of dCF, there was no deamination of either deoxyadenosine or FANA-A (Fig. 5A and B). 448 
Due to the lack of a reference compound for the deaminated form of FANA-A, we 449 
monitored the deamination by the disappearance of the FANA-A peak instead. The 450 
results shown in Fig. 5 are just a few examples from several experiments where the 451 
incubation time, substrate concentration, and/or source of serum was varied 452 
(commercially available heat-inactivated sera were also tested). A general conclusion was 453 
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that heat-inactivation only has a modest effect on adenosine deaminase. The deamination 454 
was negligible in the first hours of incubation but became a severe problem after 24 h.  455 
 456 
The roles of the P1 and P2 nucleoside transporters for FANA-A uptake were also tested 457 
in assays for the ability of the drug to inhibit [3H]-adenosine uptake in trypanosomes 458 
(Table 4, Fig. 6). As expected, FANA-A was a good competitor for the P1 transporter 459 
with a Ki value similar to the KM of adenosine itself. The result with the P2 transporter 460 
was much more surprising. The Ki value was 10 times lower than with adenosine, 461 
indicating that it seems to be a substrate with superior binding affinity (with a difference 462 
in Gibbs free energy of binding ΔG0 of 5.7 kJ/mol), suggesting that a 2´-fluorine pointing 463 
upwards in a Haworth projection actually contributes to the binding interactions with the 464 
transporter, although a hydroxy moiety at that position is not favored (Ki = 1.9 µM for 465 
Ara-A). It has previously been shown that a ‘down’-directed hydroxyl group at the 2´ 466 
position is also not favored because deoxyadenosine has greater affinity compared to 467 
adenosine (5) (Table 4). Thus we also tested the stereoisomer of FANA-A, 2´F-2´-468 
deoxyadenosine, and found that it had almost as high binding affinity as FANA-A (Table 469 
4). A fluorine at the 2´-position, in either direction, seems consequently to be favorable 470 
for high-affinity binding to the P2 transporter. In conclusion, FANA-A interacts with 471 
both types of transporters efficiently, although the P1 transporter alone appears to be 472 
sufficient for the antitrypanosomal effect.  473 
 474 
 475 
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In vivo experiments. Black C57BL/6 mice were infected with T. brucei TC221 476 
bloodstream forms, and treatment was initiated with the tested drug (Ara-AMP or FANA-477 
A) injected intraperitoneally in combination with dCF as soon as the parasites were 478 
detectable in the blood. Because Ara-A has low aqueous solubility, it was given in the 479 
form of Ara-AMP in these experiments. Ara-AMP is a prodrug, which, upon 480 
dephosphorylation to Ara-A in the blood, is able to cross the cell membrane (42). As 481 
shown in Table 5, all the mice treated with any of the two drug combinations were cured. 482 
The level of parasites in the blood decreased below the detection limit within a day after 483 
the FANA-A treatment was initiated and remained the same during the rest of the 484 
treatment and for an additional 60 days of drug-free follow up, demonstrating that all of 485 
the mice were cured. Similar results were obtained for the Ara-AMP treatment except 486 
that it sometimes took two days for the parasite levels to go below the detection limit. No 487 
obvious side effects were observed with the FANA-A treatment, whereas the Ara-AMP 488 
treatment gave some weight loss that was recovered in all mice after the treatment was 489 
finished. On average, the weight loss in the Ara-AMP treated mice was a 13 ± 2% 490 
(standard error) difference between the starting weight and the lowest weight during the 491 
treatment. No weight loss was observed in the FANA-A-treated mice. Control groups, 492 
which received dCF or only PBS, were sacrificed three days after the treatment was 493 
initiated due to heavy parasite loads. Because the dosage protocol described here was 494 
100% curative, it is likely that lower dosages or fewer administrations might still be 495 
effective, and the lower limits required for cure remain to be determined. Importantly, the 496 
mice treated with FANA-A did not suffer any overt toxic effects from the current 497 
protocol. 498 
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 499 
Discussion  500 
 501 
To date, the antitrypanosomal adenosine analogs developed against T. brucei are taken up 502 
primarily by the P2 transporter (25, 26, 43). However, because mutations in this 503 
transporter are strongly associated with resistance to current treatments (44-47), we 504 
propose that adenosine analogs that are instead taken up by the P1 transporter, or by both 505 
the P1 and P2 transporters, should be prioritized in the search for new agents against T. 506 
brucei.. Here, we have identified FANA-A as an example of such an agent. FANA-A 507 
inhibited T. brucei proliferation in the low nanomolar range, and multidrug-resistant 508 
trypanosomes lacking the P2 transporter were equally sensitive to the drug as the parent 509 
strain, showing that the P1 transporter alone is sufficient for the uptake of the drug. Yet, 510 
the uptake assays showed that FANA-A very strongly inhibits adenosine uptake by both 511 
the P1 and P2 transporters. FANA-A contains both the P2 binding H2N-C(R1)=N-R2 512 
‘amidine motif’ that is either incorporated into or attached to an aromatic ring (45, 48) 513 
and the P1 binding motif, including the N(7) and N(3) atoms of the base as well as the 3´ 514 
and 5´-hydroxyl groups of the ribose (5, 23). Thus, FANA-A provides a perfect fit for the 515 
recognition motifs of both T. brucei nucleoside transporters. The observation that the P1 516 
and P2 transporters both display very high affinity for FANA-A is consistent with the P2 517 
knockout experiment that shows that this transporter is not important for the trypanocidal 518 
activity of FANA-A. One possibility could be that FANA-A efficiently binds to this 519 
transporter but that its translocation rate is very slow (low Vmax/KM for the substrate) 520 
possibly because of a slow off-rate linked to the unusually high binding affinity, but this 521 
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can only be assessed using radiolabeled FANA-A as the substrate, which was not 522 
available. The alternative explanation is that uptake by the P1 transporters, which are 523 
encoded by several genes, is already sufficient, with the toxicity being limited by the rate 524 
of phosphorylation by adenosine kinase or the rate of incorporation into DNA, rather than 525 
the rate of uptake. 526 
 527 
The sensitivity of the parasites to FANA-A seems to be dependent on many factors, 528 
including the efficiency of uptake and phosphorylation, resistance to cleavage, and effect 529 
on DNA biosynthesis (Fig. 7). The affinity of FANA-A for the P1 transporter is as high 530 
as that of adenosine, which is one of the main physiological substrates of this transporter, 531 
and as mentioned above it is likely that the P2 transporter adds additional uptake 532 
capacity. The initial phosphorylation of FANA-A, which is carried out by adenosine 533 
kinase, is also efficient with a six times higher catalytic efficiency (kcat/KM) for the T. 534 
brucei enzyme compared to the human enzyme, although it should be remembered that 535 
phosphorylation of substrates in the cell is dependent on both the catalytic efficiency of 536 
the enzyme and its physiological concentration and that mammalian cells also have 537 
deoxycytidine kinase that can phosphorylate deoxyadenosine analogues in the cytosol 538 
(39). The efficient uptake and phosphorylation of FANA-A was confirmed in T. brucei 539 
cells, which accumulated higher concentrations of FANA-ATP than the endogenous level 540 
of ATP. Another main factor behind the efficient accumulation of FANA-ATP is that 541 
FANA-A is not recognized by TbMTAP and other cleavage activities in the cell and is 542 
thereby protected from degradation. The ultimate effect of FANA-A is that it interferes 543 
with DNA synthesis and causes DNA breaks. For nucleoside analogues, this is a very 544 
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strong indication that they are incorporated into DNA. DNA breaks have previously been 545 
observed in mammalian cells treated with F-Ara-A, which was found to be incorporated 546 
into DNA where it acted as a structural chain terminator (36). In contrast to classical 547 
chain terminators, F-Ara-A does not lack the 3´-OH group. Instead, it is the structure of 548 
the DNA that is altered in such a way that the 3´-end cannot be extended, leading to 549 
breakage-sensitive single-stranded regions in the replicated DNA (36, 49). While delayed 550 
non-obligate chain terminators allow the DNA polymerase to add a few nucleotides after 551 
the incorporation site, F-Ara-A, clofarabine (which resembles FANA-A), and many other 552 
2´-modified nucleoside analogues are pseudo-obligate, which means that they resemble 553 
classical terminators in that the 3´-end is not extended further (49, 50).      554 
  555 
Experience so far has shown that most adenosine analogues tested cross the blood-brain 556 
barrier to varying degrees (51, 52), and Ara-A given intravenously has successfully been 557 
used to cure herpes simplex brain infections in humans (53). However, the neurological 558 
side effects reported for a few Ara-A-treated patients (54), and the need to use the 559 
phosphorylated form of the drug to make it soluble, limit its applicability and appear to 560 
make FANA-A a more interesting drug candidate. Neither FANA-A nor Ara-A can be 561 
used as single agents in therapy and need to be combined with dCF, which is also called 562 
pentostatin, in order to be protected from deamination by adenosine deaminase in the 563 
mammalian blood (Fig. 7). dCF is known to cross the blood-brain barrier in monkeys 564 
(55), making it suitable for use in second-stage sleeping sickness. A possible problem 565 
with dCF is that it has been reported to be teratogenic, but only if given on day 7–8 in 566 
pregnant mice (56). However, a later study that compared mice and rabbits found that this 567 
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was a mouse-specific effect, although this has to be verified in other animal models as 568 
well if it is going to be used in pregnant sleeping sickness patients (57). Nevertheless, it is 569 
still an advantage if FANA-A can be modified in a way that it can be used as a single 570 
agent instead. One such modified analogue is 2F-FANA-A, which we found was 20 times 571 
more selective against T. brucei than the mammalian fibroblasts used as reference. 572 
However, this level of selectivity is quite modest compared to FANA-A, and we are 573 
currently experimenting with other ways of making the molecule resistant to adenosine 574 
deaminase. In conclusion, FANA-A is a promising candidate for further drug 575 
development and demonstrates that nucleoside analogues can be created that are taken up 576 
principally by the P1 nucleoside transporter, thereby avoiding the drug resistance 577 
problems associated with uptake by the P2 nucleoside transporter.  578 
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Figure legends. 
 
Fig. 1. Deoxyadenosine and adenosine analogues containing 2´-substituents oriented as in 
Ara-A. The 2´position is highlighted in the left figure. Adenosine, which is not included 
in the figure, has its 2´-hydroxyl group pointing in the same direction as in 2´C-
methyladenosine. 
 
Fig. 2. Effect of FANA-A on T. brucei TC221 proliferation, nucleotide pools, and nucleic 
acid biosynthesis. (A) Inhibition of T. brucei TC221 proliferation as a function of FANA-
A concentration. (B) Pools of ATP (∎), FANA-A triphosphate (), FANA-A 
diphosphate (), UTP (), and GTP () in T. brucei cells treated with various 
concentrations of FANA-A. (C) The effect of FANA-A on DNA biosynthesis. (D) The 
effect of FANA-A on RNA biosynthesis. All experiments were performed with 2 µM 
dCF in the growth medium, and the results are based on at least three independent 
experiments with standard errors indicated. 
 
Fig. 3. Cell cycle distribution and DNA fragmentation in FANA-A-treated T. brucei 
Lister 427 cells. (A) Cell cycle distribution in T. brucei treated with 0.2 µM FANA-A 
and 2 µM dCF (open symbols) as compared to untreated cells (filled symbols). Based on 
the number of nuclei (N) and kinetoplasts (K) and the presence of a furrow ingression, 
the cell cycle was divided into 1N1K (○, ●), 1N2K (, ), early 2N2K (, ), and late 
2N2K cells with initiated cytokinesis (□, ■). The ordinate is split into two segments to be 
able to enhance the lower part. (B) The percentage of DNA fragmentation as determined 
by the TUNEL assay on T. brucei grown in the absence (control) or presence of 2 µg/ml 
phleomycin (Phleo), 0.2 µM FANA-A, or a combination of 0.2 µM FANA-A and 2 µM 
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dCF. The results in A and B represent the average of two and three independent 
experiments, respectively, with indicated standard errors and p-values from a Student´s t-
test where the results were compared to the untreated control cells (* p < 0.05, *** p < 
0.001). 
 
Fig. 4. T. brucei and human adenosine kinase activities. (A) Enzyme activity as a 
function of phosphate concentration with T. brucei and human adenosine kinases. The 
substrates were 100 µM FANA-A with the T. brucei adenosine kinase (∎) and 100 µM 
FANA-A (□) or 100 µM adenosine () with the human adenosine kinase. (B) Enzyme 
activity as a function of the FANA-A concentration with T. brucei (∎) and human (□) 
adenosine kinases. T. brucei adenosine kinase activity with 2F-FANA-A is shown for 
comparison (♦). All experiments were performed with 3 mM ATP as the co-substrate, 
and the graphs represent the average from at least three independent experiments with 
standard errors indicated. 
 
Fig. 5. HPLC profiles showing the deamination of 1 mM deoxyadenosine (A) and 
FANA-A (B) when incubated in HMI-9 medium. The medium contained 10% heat-
inactivated fetal bovine serum, and the measurement was performed after 48 h incubation 
at 37oC. The chromatograms are shown in a staggered view where the baselines are 
shifted vertically to fit several traces in each plot.  
 
Fig. 6. Transport of [3H]-adenosine by T. brucei bloodstream forms (A) Transport of 0.1 
µM [3H]-adenosine by the B48 cell line over 30 s, in the absence (first data point) or 
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presence of unlabelled adenosine (▲) or FANA-A (□) at the indicated concentrations. 
(B) Transport of adenosine in the presence of unlabelled adenosine (▲) or FANA-A (□). 
The experiments were performed in a similar way as in panel A, but using B48 cells 
expressing the P2 transporter (B48+P2), and the experiment was performed in the 
presence of 1 mM inosine for all data points in order to block the P1 transport activity. 
Both panels are representative of at least three independent experiments with standard 
errors indicated. 
 
Fig. 7. FANA-A metabolism and mechanism of action in T. brucei. The P2 nucleoside 
transporter is not included in the figure because the P1 transporter is sufficient to give 
maximal growth inhibition by FANA-A. dCF, deoxycoformycin, ADA, adenosine 
deaminase, MTAP, methylthioadenosine phosphorylase. 
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Table 1. TbMTAP activity with its native substrate methylthioadenosine and different 
nucleoside analogues used at 100 µM. Methylthioadenosine and adenosine were used as 
positive controls for the TbMTAP and cell extract cleavage activities, respectively.  
 
Substrate TbMTAP activity 
(µmol · min-1 · mg-1) 
Cleavage in cell extracts 
(µmol · min-1 · mg-1) 
Methylthioadenosine 4.3 ± 0.2 Not analyzed 
Deoxyadenosine 16.7 ± 0.7 Not analyzed 
Adenosine 11.8 ± 0.3 0.16 ± 0.05 
Ara-A 0.0027 ± 0.0004 <0.0002 
FANA-A 0.0006 ± 0.0002 <0.0003 
2F-FANA-A <0.0002 <0.0002 
Clofarabine <0.00006 <0.0001 
2´C-methyladenosine 0.0007 ± 0.00006 <0.0003 
  
 
 
 
 
 
 
 
Table 2. Inhibition of T. brucei TC221, mouse Balb/3T3, and human HL-60 cell 
proliferation with adenosine analogues. FANA-A and 2´C-methyladenosine were given 
together with 2 µM deoxycoformycin (dCF).   
 
Nucleoside analogue T. brucei  
EC50 (µM) 
BALB/3T3 
EC50 (μM) 
HL-60 
EC50 
(µM) 
Selectivity 
Index 
FANA-A (+dCF) 0.0028 ± 0.0002 5.4 ± 1.2 2.2 ± 0.1  1900; 790 
2F-FANA-A 0.56 ± 0.11  10 ± 5  18 
Clofarabine 75 ± 17 1.24 ± 0.03  0.017 
2´C-methyladenosine (+dCF) 0.30 ± 0.07 11 ± 7  37 
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Table 3. The effect of FANA-A and 2F-FANA-A on the proliferation of T. brucei Lister 
427 (parent strain), P2 knockout cells (strain B48), TbB48 cells complemented with the 
P2 nucleoside transporter (strain B48 + P2), and T. brucei strain TC221. Pentamidine was 
used as the positive control. P-values from Student´s t-tests were obtained by comparing 
B48 vs. Lister 427, and B48 + P2 vs. B48 (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0001, ns – not significant).  
  
Strain Pentamidine 
EC50 (µM) 
FANA-A  
EC50 (µM) 
FANA-A (+dCF) 
EC50 (µM) 
2F-FANA-A 
EC50 (µM) 
Lister 427 0.0030 ± 0.0002 0.120 ± 0.001 0.014 ± 0.001 0.47 ± 0.09 
B48 0.65 ± 0.03**** 0.079 ± 0.005** 0.0072 ± 0.0004*** 0.094 ± 0.016*** 
B48 + P2 0.049 ± 0.003**** 0.060 ± 0.001* 0.0049 ± 0.0004* 0.11 ± 0.03 (ns) 
     
TC221  0.25 ± 0.06 See Table 2 See Table 2 
 
 
 
 
 
 
Table 4. Adenosine transporter assay. 
 
Compound P1 transporter 
Km or Ki (µM) 
ΔG0  
kJ/mol 
P2 transporter 
Km or Ki (µM) 
ΔG0 
kJ/mol 
Adenosine1 0.41 ± 0.08 −36.8 0.92 ± 0.06 −34.5 
FANA-A 0.48 ± 0.11 −36.1 0.09 ± 0.02 −40.2 
2´F-deoxyadenosine 0.06 ± 0.01 −41.1 0.19 ± 0.03 −38.3 
Ara-A ND  1.9 ± 0.5 −32.6 
Deoxyadenosine2 0.19 ± 0.02 -38.3 0.23 0.04 -37.9 
1KM value for adenosine, the other values are Ki values (inhibition constants) determined 
by competition against [3H]-adenosine transport.  
2Values used from De Koning and Jarvis, 1999 (5), included for comparison.  
ND, not determined. 
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Table 5. Effect of intraperitoneal FANA-A and Ara-AMP treatments on T. brucei-
infected mice. The dose was given in the morning and evening on day 1, 3, and 5. 
 
 
Drug Dose (mg/kg) × 2 ×3 Cure rate 
Ara-AMP (+dCF) 200 (+ 0.25 dCF) 10/10 
FANA-A (+dCF) 200 (+ 0.25 dCF) 10/10 
dCF 0.25 0/5 
Only PBS - 0/7 
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